JP2010505850A5 - - Google Patents

Download PDF

Info

Publication number
JP2010505850A5
JP2010505850A5 JP2009531472A JP2009531472A JP2010505850A5 JP 2010505850 A5 JP2010505850 A5 JP 2010505850A5 JP 2009531472 A JP2009531472 A JP 2009531472A JP 2009531472 A JP2009531472 A JP 2009531472A JP 2010505850 A5 JP2010505850 A5 JP 2010505850A5
Authority
JP
Japan
Prior art keywords
taxane
pharmaceutical composition
recombinant mva
antigen
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009531472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505850A (ja
JP5964540B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/021436 external-priority patent/WO2008045346A2/en
Publication of JP2010505850A publication Critical patent/JP2010505850A/ja
Publication of JP2010505850A5 publication Critical patent/JP2010505850A5/ja
Application granted granted Critical
Publication of JP5964540B2 publication Critical patent/JP5964540B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009531472A 2006-10-06 2007-10-05 Mvaを使ってがんを処置する方法 Active JP5964540B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85003106P 2006-10-06 2006-10-06
US60/850,031 2006-10-06
PCT/US2007/021436 WO2008045346A2 (en) 2006-10-06 2007-10-05 Recombinant modified vaccinia ankara encoding a her-2 antigen for use in treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014047741A Division JP6124822B2 (ja) 2006-10-06 2014-03-11 Mvaを使ってがんを処置する方法

Publications (3)

Publication Number Publication Date
JP2010505850A JP2010505850A (ja) 2010-02-25
JP2010505850A5 true JP2010505850A5 (enExample) 2010-08-19
JP5964540B2 JP5964540B2 (ja) 2016-08-03

Family

ID=39283388

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009531472A Active JP5964540B2 (ja) 2006-10-06 2007-10-05 Mvaを使ってがんを処置する方法
JP2014047741A Active JP6124822B2 (ja) 2006-10-06 2014-03-11 Mvaを使ってがんを処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014047741A Active JP6124822B2 (ja) 2006-10-06 2014-03-11 Mvaを使ってがんを処置する方法

Country Status (11)

Country Link
US (2) US7807146B2 (enExample)
EP (2) EP2073837B1 (enExample)
JP (2) JP5964540B2 (enExample)
AU (1) AU2007307080B2 (enExample)
CA (1) CA2665068C (enExample)
DK (2) DK2596801T3 (enExample)
ES (1) ES2500465T3 (enExample)
IL (1) IL197633A (enExample)
NZ (2) NZ597998A (enExample)
PT (1) PT2073837E (enExample)
WO (1) WO2008045346A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101676389A (zh) * 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
EP2073837B1 (en) * 2006-10-06 2014-06-25 Bavarian Nordic Inc. Recombinant modified vaccinia ankara virus encoding a her-2 antigen in combination with a taxane for use in treating cancer
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
WO2012059376A1 (en) * 2010-11-02 2012-05-10 Telefonaktiebolaget L M Ericsson (Publ) Methods and devices for media description delivery
US9463238B2 (en) 2011-12-09 2016-10-11 Bavarian Nordic A/S Recombinant poxvirus vector comprising tetanus toxin fragment C
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
US20150283220A1 (en) * 2012-10-19 2015-10-08 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
EP2777711A1 (en) * 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
EP3017605B1 (en) 2013-07-03 2022-12-07 Koninklijke KPN N.V. Streaming of segmented content
AU2014340201B2 (en) * 2013-10-23 2019-02-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
WO2016144564A2 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
US10736962B2 (en) 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US10512662B2 (en) 2016-02-25 2019-12-24 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
US11052147B2 (en) 2017-05-15 2021-07-06 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3061678A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US20210177964A1 (en) * 2017-11-06 2021-06-17 Memorial Sloan Kettering Cancer Center Heat-inactivated vaccinia virus as a vaccine immune adjuvant
MX2021003013A (es) 2018-09-15 2021-08-11 Memorial Sloan Kettering Cancer Center Poxvirus recombinantes para inmunoterapia contra cáncer.
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN114980920A (zh) 2019-11-18 2022-08-30 詹森生物科技公司 基于突变体calr和jak2的疫苗及其用途
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン,インコーポレイティド 万能dr−結合性ペプチドを用いる免疫応答の改変
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
DE19729279A1 (de) 1997-07-09 1999-01-14 Peter Hildebrandt Urologisches Implantat, insbesondere Gefäßwandstütze für den Urinaltrakt
CA2345817C (en) 1998-10-05 2013-02-12 M&E Biotech A/S Novel methods for therapeutic vaccination
DE10042598A1 (de) 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
CN101676389A (zh) 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
US20040191218A1 (en) * 2001-09-26 2004-09-30 Emlen James W Pharmaceutical compositions and methods for treating cancer
BR0316010A (pt) * 2002-11-06 2005-09-13 Cyclacel Ltd Combinação
EP1575601B1 (en) * 2002-12-16 2015-07-01 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant vaccine viruses expressing il-15 and methods of using the same
CN1511549A (zh) * 2002-12-27 2004-07-14 张小丽 含有黄芩的抗肿瘤、抗炎症及肿瘤预防药物的组合物
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
JP2006528697A (ja) * 2003-05-16 2006-12-21 イデラ ファーマシューティカルズ インコーポレイテッド イムノマーを化学療法剤と組み合わせて用いる、癌の相乗的処置
EP2090586A1 (en) * 2003-06-25 2009-08-19 BN ImmunoTherapeutics, Inc. Purification of her-2 variants
EA008827B1 (ru) 2003-06-25 2007-08-31 Фармекса А/С Очистка вариантов her-2
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
UA100836C2 (ru) * 2005-02-23 2013-02-11 Бавариан Нордик А/С Применение модифицированного вируса осповакцины анкара (mva) для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов
EP2073837B1 (en) 2006-10-06 2014-06-25 Bavarian Nordic Inc. Recombinant modified vaccinia ankara virus encoding a her-2 antigen in combination with a taxane for use in treating cancer

Similar Documents

Publication Publication Date Title
RU2009121568A (ru) Комбинации и способы введения терапевтических агентов и комбинированная терапия
RU2012106620A (ru) Комбинации и способы введения терапевтических средств и комбинированной терапии
NZ707377A (en) Combination therapy methods for treating proliferative diseases
JP2013541583A5 (enExample)
RU2010132581A (ru) Способы терапии заболеваний легких
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2015522603A5 (enExample)
WO2005089448A3 (en) Administration of cisplatin by inhalation
JP2013544892A5 (enExample)
CN101905006B (zh) 一种治疗跌打损伤外用药
JP2010500284A5 (enExample)
CN101049337A (zh) 一种治疗疔疖疮痈的药物及其制备方法
JP2017502058A5 (enExample)
JP2017514829A5 (enExample)
RU2010140888A (ru) Улучшенные противораковые терапии
JP2011500650A5 (enExample)
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
CN102805847B (zh) 一种治疗痹症的药
CN104606655A (zh) 一种用于铺灸治疗风寒湿痹症的蒜姜组合物及其应用
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
JP2010521488A5 (enExample)
CN102114116B (zh) 一种治疗咽炎的中药
CN202044647U (zh) 治疗甲状腺病的护脖
RU2007129567A (ru) Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
EA200801388A1 (ru) Фармацевтическая композиция для лечения туберкулеза и заболеваний, опосредованных helicobacter pilory, на основе полимерных наночастиц, способ ее получения и способ лечения